Therefore, targeting the Abl kinases with small‐molecule inhibitors, which were initially developed to treat patients with hematological or gastrointestinal tumors, might be used to treat distinct pathologies where Abl activation is a key driver of disease. Here, ABL1 is linked to digestive system neoplasm.